According to he International Association for the Study of Pain, pain is “an unpleasant sensory and emotional experience associated with actual or potential tissue damage, or described in terms of such damage”.
Pain is a complex event that can occur upon a noxious trigger or even without a detectable stimulus. When nociception is involved, a signal is processed in peripheral and central nervous systems. Multiple actors in this pathway have been identified and are thus putative target for designing therapeutics.
Chronic pain treatment is the focus of thousands of clinical trials and in this field migraine research has progressed during the last decades with the discovery of CGRP (Calcitonin gene-related peptide). CGRP is released during migraine attacks and can trigger migraine in patients, and CGRP receptor antagonists can abort migraine. This led to the development of small molecule CGRP receptor antagonists for acute and preventive treatment of migraine and monoclonal antibodies against CGRP mechanisms for migraine prevention. Data are also suggesting that CGRP may have a role in non-headache pain conditions. Increases in circulating CGRP levels have been noticed during hemodialysis, pregnancy, exacerbation of asthma and in cases of medulalary thyroid carcinoma.
Focused products:
CGRP ELISA kits:
Bertin Bioreagent offers ELISA kit for CGRP quantification in human and rodent samples. Those kits are widely used by the scientific community and are extensively cited. Please refer to the product pages to have a list of publications.
For your preanalytical phases, you might need CGRP affinity sorbent and/or C-18 Solid Phase Extraction (SPE) Cartridges.
